Spots Global Cancer Trial Database for retinal vein occlusion
Every month we try and update this database with for retinal vein occlusion cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Branch Retinal Vein Occlusion (BRVO) | NCT01976338 | Macular Edema S... | Ranibizumab 0.5... Sham injection | 18 Years - | Novartis | |
An Extension Study to Evaluate Safety and Tolerability of Ranibizumab in Macular Edema Secondary to Retinal Vein Occlusion (Cohort 2) | NCT01442064 | Macular Edema Retinal Vein Oc... | Ranibizumab 0.5... | 18 Years - | Genentech, Inc. | |
An Extension Study to Evaluate Safety and Tolerability of Ranibizumab in Macular Edema Secondary to Retinal Vein Occlusion (Cohort 2) | NCT01442064 | Macular Edema Retinal Vein Oc... | Ranibizumab 0.5... | 18 Years - | Genentech, Inc. | |
Vitreous Level Of Tumor Necrosis Factor Alpha In Patients With Retinal Vein Occlusion | NCT05532475 | Retinal Vein Oc... | measurement of ... | 18 Years - | Kasr El Aini Hospital | |
Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Branch Retinal Vein Occlusion (BRVO) | NCT01976338 | Macular Edema S... | Ranibizumab 0.5... Sham injection | 18 Years - | Novartis | |
Vitreous Level Of Tumor Necrosis Factor Alpha In Patients With Retinal Vein Occlusion | NCT05532475 | Retinal Vein Oc... | measurement of ... | 18 Years - | Kasr El Aini Hospital | |
Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Branch Retinal Vein Occlusion (BRVO) | NCT01976338 | Macular Edema S... | Ranibizumab 0.5... Sham injection | 18 Years - | Novartis | |
Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO) | NCT00943072 | Macular Edema S... | VEGF Trap-Eye 2... Sham | 18 Years - | Regeneron Pharmaceuticals | |
Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO) | NCT00943072 | Macular Edema S... | VEGF Trap-Eye 2... Sham | 18 Years - | Regeneron Pharmaceuticals |